TORAY RAYTELA® Polymer Optical Fiber Cable Provides 1.8 Times Larger Lighted Area For Minimally Invasive Surgeries.

Polymer Optical Fiber Cable From TORAY

TORAY RAYTELA® POF Provides 1.8 Times Larger Lighted Area

Raytela® POF has a unique polymer design structure which transmits light at a large, 79 degree angle through the core, providing up to 1.8 times more light.

NEW YORK, NEW YORK, UNITED STATES, October 27, 2020 /EINPresswire.com/ — Toray, Industries Inc., Raytela® POF has a unique polymer design structure which transmits light at a large, 79o angle through the core, providing up to 1.8 times more light broadcasting at the distal end than conventional polymer cables. This light amplification advantage is designed to improve minimally invasive surgery outcomes. The Raytela advantage compares to competitive, same sized polymer optical fiber cable which has only 60o degree angle light transmission.

Raytela’s is designed to provide more effective endoscopy, ureteroscopy, ophthalmic surgeries and other challenging procedures that require devices that are increasingly smaller. The unique Raytela design allows navigation of these smaller devices through more tortuous paths than ever before. Raytela also meets these increasingly demanding needs for high quality imaging and flexibility without fracturing. Because Raytela is very flexible and is a highly efficient transmitter of high intensity light, its greater light efficiency transmission means that it requires less intensity at the light source. An additional special design feature is its significantly wider degree of light broadcasting at the distal end. This combination of special capabilities results in significantly smaller diameter devices that require fewer light cables.

In addition to its smaller diameter design feature, Raytela optical fiber can negotiate tight 9mm radius bends and bend back upon itself 180° with no loss in light intensity. When compared to glass fibers used in many current devices, Raytela has greater fracture resistance and longer life.

Manufactured in accordance with MAF3188, Raytela has FDA Master File registration application. It is available in 5 dimeters from 250 μm to 1500 μm,

For more information about RAYTELA Polymer Optical Fiber, call 212-697-8150 to learn more. Or Email: med@Toray-intl.com www.toray.us Toray Industries, Inc., 461 Fifth Ave, 9th Fl., New York NY 10017

chris madison
anderson madison advertising inc
+1 952-835-5133
email us here


Source: EIN Presswire

TriageNow Completes SOC2 Compliance With Help From RyanTech

When Employee Care Really matters

TriageNow, a premiere telephonic nurse triage service, is proud to announce compliance with SOC2.

Helping businesses stay safe from cybercrime is our core focus in everything we do.”

— Ryan McMillen, Director of Business Development RyanTech

GILBERT, AZ, UNITED STATES, October 27, 2020 /EINPresswire.com/ — SOC 2 is specifically designed for service providers storing customer data in the cloud. That means SOC 2 applies to nearly every SAAS company, as well as any company that uses the cloud to store its customers’ information.

As a precursor to the Workers’ Compensation process, TriageNow is a time-of-injury solution that guides employees to the appropriate level of care.  By doing so, companies large and small nationwide experience an average of 40% reduction in their work comp claims by using this triage service. Satisfying the requirements for SOC2 Compliance ensures client data is securely maintained.

“Throughout the Pandemic, TriageNow has been thriving because we had the tools in hand which gave the management team the flexibility to pivot and still serve our customers with the same level of service and care.” Craig Arnett, CTO TriageNow

“Helping businesses stay safe from cybercrime is our core focus in everything we do. Working with TriageNow to showcase security solutions based on the most secure Cloud solution from Microsoft was a great opportunity for our team to assist in implementing these policies and then following with a successful SOC2 Compliance audit.” Ryan McMillen, Director of Business Development Ryan Tech Inc.

To read the full case study CLICK HERE

About TriageNow
TriageNow (www.triagenow.net) is a technology first company. TriageNow employs technology to improve and expedite the process for the injured employee. They address the workplace injury at its origin, focusing on early intervention and care that helps reduce injury costs while improving the injury care process for everyone involved. TriageNow is located in Gilbert, AZ and services clients large and small nationwide.

About RyanTech, Inc.
RyanTech (www.ryantechinc.com) is a Cloud Solution Provider that crafts end-to-end systems uniquely designed for your business. Several of our areas of expertise are Email Systems, Business Wifi, and Office 365 along with keeping your network and tech stack safe from intrusion and cyber attacks. We are longtime experts in application development, network solutions, and cloud computing in Azure.

Ryan McMillen
Triage Now
email us here


Source: EIN Presswire

PRO-DIP®’s Next Gen Oral Nutrient Pouch Launches with Leading U.S. Military Equipment Supplier ADS, Inc.

Peter St. Lawrence's simple yet groundbreaking Oral Pouch invention is a leap forward in beneficial nutrient delivery system technology.

Patent Pending Oral Nutraceutical Pouch – Welcome to the future.

Some features of the Pouch: Natural B Vitamins, Caffeine, Vitamin C, Beta-Alanine Taurine and more. Direct, fast and efficient nutrient uptake. 1 Pouch = 1 cup of coffee. Contents of Pouch can last up to 40 minutes while energizing effects can last up to

PRO-DIP®’s new and innovative hands-free “during-activity” nutrient delivery system pouches are garnering mainstream attention.

“We are honored to collaborate/work with ADS to distribute this innovation to thousands in the U.S. DOD,” said PRO-DIP Energy’s Inventor and CEO Peter St. Lawrence.

PRO-DIP® Inventor and CEO Peter St. Lawrence at ADS, Inc. in Virginia.

PRO-DIP®, patent-pending world leader in Nutraceutical Oral Pouch technology has teamed up ADS, Inc. to distribute to the U.S. Military.

For all the Enlightened Warriors out there;……this is for you……"What's Impossible"?”

— Peter St. Lawrence (CEO)

SILICON VALLEY, CALIFORNIA, UNITED STATES, October 27, 2020 /EINPresswire.com/ — PRO-DIP® Energy powered by Acenzia, the patent-pending world leader in nutraceutical oral pouch manufacturing has teamed up with Virginia-based ADS, Inc. this past week to distribute PRO-DIP’s flagship ION Energy pouches to the U.S. Military. ADS is a leading distributor of top-end tactical equipment and systems to the military both domestically and abroad. This collaboration greatly adds to PRO-DIP’s existing specialty distribution channels and significantly increases the product’s presence in a niche market that is always looking for innovation. According to Statista.com, the military is one of highest demographics in smokeless tobacco and nicotine pouch usage. PRO-DIP® Pouches, being tobacco and nicotine free, are FDA registered dietary supplement pouches filled with nutritious vitamins and minerals. The Pouch delivery system is similar to that used for smokeless tobacco, which makes it the perfect alternative for military personnel looking to quit or reduce their tobacco and nicotine consumption. Even more exciting are the performance elevating benefits that the soldiers may experience on the battlefield and during training.
ADS is a leading value-added logistics and supply chain solutions provider that proudly serves all branches of the U.S. Military, federal, state and local government organizations, law enforcement agencies, first responders, partner nations and the defense industry. Headquartered in Virginia Beach, VA, ADS is a top Department of Defense Contractor focused on solving customers’ challenges by providing the best product and service offerings, the broadest array of procurement options and legendary customer service.
“We are honored to collaborate/work with ADS to distribute this innovation to thousands in the U.S. DOD,” said PRO-DIP Energy’s Inventor and CEO Peter St. Lawrence. “Nothing makes us prouder than to do our small part to serve those who do the big part; serving the ideals and protecting those that make this great Country what it is. We believe this partnership will help us meet the ever-expanding demand for innovations that make the lives of military personnel a little better.”
For sale in the United States since May 2019, the novel PRO-DIP® ION Energy pouches deliver flavorful bursts of vitamins and natural energy supplements through small, semi-permeable sachets placed in the mouth, between the gum and cheek or lip. The initial burst of supplements is followed by extended absorption of the nutrients, providing long-lasting energy, even at high-exertion levels. With its hand-free ease of consumption, the energy-rich pouches are an alternative to traditional sports supplements, and deliver a daily serving of natural vitamins and nutrients for the endurance and stamina required during exercise and sports. The invention of the pouch delivery system for nutraceuticals continues to gain mainstream interest from health product manufacturers, medical organizations, big pharma, the military, space organizations, CBD/hemp companies, humanitarian aid groups and the list goes on. Midway through 2019, PRO-DIP started getting contacted by some of these major U.S. and international companies seeking opportunity to add the Pouch to expand and innovate their current product lines. The opportunity to initiate a project of this magnitude was something the founders of PRO-DIP Energy® couldn’t ignore.
Exiting a closed-door emerging food tech summit in New York, Peter St. Lawrence stated;
“In this modern age we’re very fortunate to be among the few who are given the rare and special opportunity to pioneer something completely original for the global market. The Oral Pouch itself may be our real “product,” as we’re now embarking on a mission to build something much greater than just a brand, we’re building an entire product category. What started as an idea five years ago now feels like a life’s-calling for everyone involved. We couldn’t be more pumped for this, after all we’re “energy” guys, haha (laugh). We’re here to serve-up useful innovations that people can use today. This is going to be an unbelievable ride and we’re all-in.”
For more information visit: www.PRODIP.pro

——————
Safe Harbor Statement
In addition to statements of current and historical fact, this Press Release contains forward-looking statements. The words "forecast," "will," "intend," "anticipate," "project," "intend," "expect," "should," "believe" and similar expressions are intended to identify forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Press Release, we caution you that these statements are based on a combination of facts and factors currently known by PRO-DIP® and its projections of the future, about which it cannot be certain. These forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors of the Company. Accordingly, all forward-looking statements should be evaluated with an understanding of their inherent uncertainty. Except as required by law, PRO-DIP® assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Kim Ulacher
PR
team@prodip.pro
Visit us on social media:
Facebook
Twitter
LinkedIn

“Live Your Adventure”


Source: EIN Presswire

3 Steps to Take Now to Reduce the Risk of Legionella in a Building’s Water System

Hyperion Biotechnology a Certified Legionella Testing Laboratory

Hyperion Biotechnology a Certified Legionella Testing Laboratory

As businesses reopen, owners should check the water safety of their buildings. Hyperion provides water testing to help owners monitor the risk of Legionella.

Proactive water sampling and testing supports building owners in maintaining a safe environment for residents, visitors, and guests.”

— Dr. John Kalns

SAN ANTONIO, TEXAS, UNITED STATES, October 27, 2020 /EINPresswire.com/ — With the current focus on limiting the spread of coronavirus as hotels, schools, and businesses reopen, building owners also need to maintain the safety of their building’s water system. Specifically, the potential for Legionella bacteria growth due to low water use for prolonged periods of time is higher than if buildings were in full operation. Legionella is a naturally occurring bacteria in the environment but can be dangerous to humans when it grows in a building’s water system. If it spreads in a building’s system, Legionella may be transmitted to people by mist or droplets in the air from faucets, fountains, and other water sources. When breathed in, the bacteria can cause Legionnaires’ disease which is a dangerous form of pneumonia. By taking the following steps, building owners can reduce the risk of Legionella bacteria growth and confirm the bacteria are not in a building’s water system.

Step 1: Learn about the dangers of Legionella bacteria and how prevention of its growth in a building’s water system can help reduce the risk of Legionnaires’ disease. All building owners and facility managers should review the Centers for Disease Control and Prevention (CDC) information on the Legionella home page. Healthcare facilities can also review requirements from the Department of Health and Human Services to Reduce Legionella Risk in Healthcare Facility Water Systems at https://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/SurveyCertificationGenInfo/Policy-and-Memos-to-States-and-Regions-Items/Survey-And-Cert-Letter-17-30-

Step 2: Develop and follow a water management plan. CDC provides information from conducting a Legionella risk assessment to implementing a water management plan to guidelines directly related to reopening after coronavirus shutdowns. Review all guidance at the CDC's Water Management Plan webpage.

Step 3: Monitor the effectiveness of Legionella risk reduction actions by conducting routine sampling and testing the building’s water for Legionella bacteria. The only way to confirm that Legionella bacteria is not present in the water system is to test the water.

“We too often receive requests for analysis of a building’s water after there has been a report of someone becoming ill,” says Dr. John Kalns, Hyperion Biotechnology’s Legionella testing expert. Steps 1 and 2 above offer guidelines to reduce risk while Step 3 is the only way to validate that Legionella bacteria is not growing. Dr. Kalns states, “Proactive water sampling and testing supports building owners in maintaining a safe environment for residents, visitors, and guests. If Legionella is detected during routine sampling, there are approaches that can be taken immediately to help reduce the risk of the bacteria spreading before people become ill with Legionnaires’ disease.”

About Hyperion
Hyperion Biotechnology is an environmental microbiology laboratory specializing in Legionella water testing. Hyperion holds CDC Environmental Legionella Isolation Techniques Evaluation (CDC ELITE) and Environmental Microbiology Laboratory Accreditation Program (EMLAP) certifications. Additionally, Hyperion has expertise in biomedical research and development with discoveries in salivary biomarkers to objectively measure fatigue levels. Hyperion delivers high-quality research and services for government and commercial customers and maintains a CLIA certified laboratory. Hyperion is a Woman-Owned, Service-Disabled Veteran-Owned small business. Visit Hyperion's website for more information.

Janel Callan
Hyperion Biotechnology, Inc.
+1 210-493-7452
info@hyperionbiotechnology.com
Visit us on social media:
Twitter
LinkedIn


Source: EIN Presswire

Numly™ Partners with Mirrah to Launch 'Leadership Habits with Art' Workshop Series for Employee Engagement

Numly Innovates with Mirrah to Launch 'Leadership Habits with Art' Workshop Series

Numly Innovates with Mirrah to Launch ‘Leadership Habits with Art’ Workshop Series

Numly™ joins hands with Mirrah, a design company, that connects people with art, to innovate in Employee Engagement.

CUPERTINO, CALIFORNIA, USA, October 27, 2020 /EINPresswire.com/ — Numly™, Inc., a leading provider of Talent Performance Employee Engagement solutions for enterprises, joins hands with Mirrah, a design company that connects people with art, to innovate in Employee Engagement.

With this partnership, Numly aims to provide a series of art-based workshops that would be mapped to various leadership skill sets. The aim of these workshops is to provide an innovative way to engage teams together to work on skills that are integral to career development. By taking an artistic approach, Numly aims to challenge attendees to take a deeper look at their strengths and work on gaps through innovative techniques.

Numly and Mirrah will collaborate to create series of workshops, including Big Picture and Café Sessions, all delivered through interactive online meetings. All sessions will feature interactive art, peer-to-peer learning and sharing activities.

Delivered in the form of interactive remote/digital/online learning sessions, the art workshops will enable people to build a unique stack of skills to stand out in the crowd, develop a creative mindset to grow and lead, and think laterally to solve bigger problems and achieve goals. They are ideally suited for cross-functional teams, middle / junior management, and teams focused on execution even when working-from-home (WFH).

“At Mirrah, we believe that when learning meets creativity, the results are vibrant and unique. Likewise, our live café sessions and workshops are designed for companies to enable their teams to look at the world in a different lens – a more colorful and creative one. We’re excited about this collaboration with Numly and together, we believe, we can transcend/push boundaries of learning and development.” said Kaavya Sampath & Pooja Shirali, Co-founders of Mirrah.

Madhukar Govindaraju, Founder & CEO of Numly added, “I believe learning is a continuous process. And there is no more creative way to adopt new skills than through Art. Our aim is to help companies push their employees to adopt necessary skills that are vital to help build their pipeline of leaders. By joining hands with Mirrah, we aim to help, not just Individuals looking to develop strategy and creativity skills, but also managers and leaders who wish to work on their strategy and their entrepreneurial growth mindset and habits.”

Earlier this year, Numly was also named a Hot Vendor by Aragon Research for Employee Engagement, 2020.

About Numly, Inc. (www.numly.io)
Numly™'s mission is to measurably improve employee engagement and employee performance through People Connections, Internal Coaching and (Hard + Soft) Skills Development. NumlyEngage™ is an AI-enhanced platform that enables coaching as an extension of eLearning, making it possible for organizations to tap into employees’ hard and soft skills and empower them to coach each other in a structured manner, while leveraging third-party learning content, expert coaches and built-in, AI-enabled coaching programs tailored for all corporate functional groups such as Sales, Customer Success, R&D/Engineering, Women Leaders, New-hires, New Managers, etc. NumlyEngage™ helps organizations accelerate revenue, increase performance, and improve employee engagement, especially in the post COVID-19 era of working-from-home (WFH).

About Mirrah:
Mirrah is a design company based in Bangalore, India that focusses on bringing people closer to art through their DIY products and creativity workshops. Their innovative products and services aim to rekindle the joy of art and creativity and to bring out the artist hidden within everyone.

Shalini Ramakrishnan
Numly™, Inc.
+44 7586 575932
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Malaria Diagnostics Market Statistics | Top Reasons for Boost the Industry | Novartis AG, Access Bio, Atlas Medical,

Malaria Diagnostics Market

Malaria Diagnostics Market

global malaria diagnostics market is expected to reach $1,085,106 thousand by 2026, registering a CAGR of 5.1% from 2019 to 2026.

PORTLAND, OREGON, UNITED STATES, October 27, 2020 /EINPresswire.com/ — According to the report, the global malaria diagnostics industry was estimated at $728,870 thousand in 2018, and is expected to hit $1,085,106 thousand by 2026, registering a CAGR of 5.1% from 2019 to 2026.

Drivers, restraints, and opportunities:

Rise in incidence of malaria, increase in healthcare expenditure among people, and surge in adoption of malaria diagnostics tools across the world drive the growth of the global malaria diagnostics market.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/285

The major factor that contributes to the growth of malaria diagnostics market include rise in prevalence of malaria in developing countries. Furthermore, rise in awareness initiatives by governments and surge in research for new malaria diagnostics are the factors that boost the growth of the market. However, lack of awareness about healthcare in developing countries is the major factor that restricts growth of the malaria diagnostics market. Conversely, growth opportunities exhibited by emerging economies is expected to offer lucrative opportunities during the forecast period.

Frontrunners in the industry-

Access Bio. Inc.
Siemens AG.
Bio-Rad Laboratories, Inc.
Premier Medical Corporation Pvt Ltd.
Atlas Medical
Biomérieux SA
Meridian Bioscience Inc.
Novartis AG
Abbott Laboratories
Olympus Corporation

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/285

Key Findings of the Study:

o Rapid diagnostic tests segment occupied approximately half the share of the global malaria diagnostics market in 2018.
o The molecular diagnostic tests segment is anticipated to grow with the highest CAGR throughout the forecast period.
o The hospitals segment accounted for one-thirds share of the market in 2018.
o Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA.

LAMEA to maintain the top status till 2026, North America to grow at the third highest CAGR-

Based on geography, LAMEA contributed to 94% of the global malaria diagnostics market revenue in 2018, and is anticipated to maintain the lion's share till 2026. At the same time, the Asia-Pacific region would showcase the fastest CAGR of 6.1% during the study period. Surge in awareness regarding the use of antimalarial drugs in this region has propelled the growth. However, North America would register a CAGR of 4.1% by 2026.

Access full Report @ https://www.alliedmarketresearch.com/malaria-diagnostics-market

The rapid diagnostic tests segment to lead the trail by 2026-

Based on product type, the rapid diagnostic tests segment accounted for more than two-fifths of the global malaria diagnostics market share in 2018, and is expected to retain its dominance by 2026. Surge in healthcare expenditure in developing countries has propelled the market growth. The molecular diagnostic tests segment, on the other hand, would register the fastest CAGR of 6.0% throughout the forecast period. Rising awareness among people regarding early diagnosis of malaria and the wide array of benefits offered by drug molecular diagnostic tests spur the growth of the segment.

Questions answered in the Malaria Diagnostics Market research report:

• Which are the leading market players active in the Malaria Diagnostics Market ?
• What are the current trends that will influence the market in the next few years?
• What are the driving factors, restraints, and opportunities in the Malaria Diagnostics Market ?

Similar Reports:

Pain Management Devices Market Opportunity Analysis & Forecast, 2020-2026

Dental Liners and Bases Market Opportunity Analysis & Forecast, 2018-2023

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Analytics LLP
+1 800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

ACI’s Celebrated Annual Conference on Women Leaders in Life Sciences Law is taking place virtually November 17-18, 2021

Conference on Women Leaders in Life Sciences Law takes place November 17-18, 2020 in a virtual format.

Conference on Women Leaders in Life Sciences Law takes place November 17-18, 2020 in a virtual format.

Women delegates seated around a table at the 2019 Conference on Women Leaders in Life Sciences Law.

Delegates at the 2019 Conference on Women Leaders in Life Sciences Law. The 2020 event will take place November 17-18, 2020 in a virtual format.

3 women speakers sitting at a table at the 2019 Conference on Women Leaders in Life Sciences Law.

Speakers at the 2019 Conference on Women Leaders in Life Sciences Law. The 2020 event will take place November 17-18, 2020 in a virtual format.

The Only Event in the Life Sciences Industry Increasing the Prominence of Women through Professional Development, Substantive Legal Discussion, & 1:1 Networking

This is one of the most meaningful conferences I have attended. Not only is it informative and insightful, it's about creating connections, inspiration & motivation to grow through shared experiences!”

— Deborah A. Logan, Associate General Counsel, EMD Serono

BOSTON, MA, UNITED STATES, October 27, 2020 /EINPresswire.com/ — The American Conference Institute is presenting it’s highly anticipated 7th Annual Conference on Women Leaders in Life Sciences Law next month on November 17-18, 2020. For the first time in its history, the conference will be taking place in an interactive, virtual format with online workshops, virtual “meet and greets”, 1:1 networking opportunities, and many more avenues that foster candid discussions, valuable collaboration, and meaningful connection.

The Conference on Women Leaders in Life Sciences Law brings together a remarkable group of senior-level women legal executives from the life sciences industry to discuss the challenges and opportunities facing women in this industry, as well as to foster communication between like-minded individuals about the key legal developments for the pharmaceutical, biotech, and medical device industries.

Key companies in attendance include:

• Alnylam Pharmaceuticals
• Amgen
• Bayer
• Boehringer-Ingelheim
• Boston Scientific
• Bristol-Myers Squibb
• Broad Institute
• Eisai
• Eli Lilly and Company
• EMD Serono
• FORMA Therapeutics
• Incyte
• Merck
• Millendo Therapeutics
• Moderna
• Nexus Pharmaceuticals
• Selecta Biosciences
• Stoke Therapeutics
• Surface Oncology
• Takeda
• Vertex Pharmaceuticals
• …and more!

Key program sessions include:

• Politics, Policy and Projections: What Does the Current Election Climate Mean for Women and Life Sciences?
• Mastering the Art of “Tooting Your Own Horn”: Valuable Tools for Self-Marketing as a Woman in the Life Sciences Industry and Being Your Own Best Advocate
• Increasing Our Focus on the “Inclusion” Piece of D&I: Understanding How We Can Better Include, Support and Retain Our Female Talent in the Life Sciences Industry
• Artificial Intelligence and the Not-So-Distant-Future: Gaining an Understanding of How the Latest AI Capabilities are Transforming the Life Sciences Industry
• Breaking Through Bias: Overcoming Gendered Perceptions in the Workplace, Boardroom and Courtroom
• …and more!

View our Full Conference Agenda >
Register to Secure Your Spot >

More on this Event:

This conference brings together in house and private practice professionals from the Pharmaceutical, Biotechnology, and Medical Device industries, well-versed in patents, IP, fraud and abuse compliance/enforcement, products liability, regulatory, M&A, and transactional law, and more providing the most conducive setting for networking and career development between female legal, business, and compliance professionals.

The Conference on Women Leaders in Life Sciences Law is part of the American Conference Institute’s Life Sciences Conference Series and aims to promote diversity and increase the prominence of women in the legal community through substantive legal discussion, professional development, and woman-to-woman networking. Our conferences provide industry-specific forums for female powerbrokers to unite and discuss the substantive legal developments, challenges, and opportunities facing women in their respective industries as well as provide them with the business contacts and communication and leadership skills necessary for continued success and career advancement.

Amy Au
American Conference Institute
A.Au@AmericanConference.com
Visit us on social media:
Twitter
LinkedIn


Source: EIN Presswire

Internal Trauma Fixation Devices Market Share Analysis, Advancement, Key Players: Stryker Corporation, DePuy Synthes

Internal Trauma Fixation Devices Market

Internal Trauma Fixation Devices Market

Global Internal Trauma Fixation Devices Market is projected to reach $12,693 million by 2025, growing at a CAGR of 6.4% from 2018 to 2025

PORTLAND, OREGON, UNITED STATES, October 27, 2020 /EINPresswire.com/ — The report offers detailed analyses of the top investment pockets, drivers & restraints, market size & estimations, key growth strategies, and competitive landscape. According to the report, the global internal trauma fixation devices market was valued at $7.65 billion in 2017 and is estimated to reach $12.69 billion by 2025, registering a CAGR of 6.4% from 2018 to 2025.

Get sample copy of this report @ https://www.alliedmarketresearch.com/request-sample/804

The report segments the global internal trauma fixation devices market based on product, material, end user, and geography. With reference to product, the market is bifurcated into closure devices and bone cement. The increase in the prevalence of accidents and sports injuries along with the rise in geriatric population drives the growth of the global internal trauma fixation devices market. During the forecast period, technological advancement and increasing healthcare infrastructure are factors that would boost market growth as well. However, complications and allergies associated with such devices are expected to hinder market growth to an extent

Key Findings of the Internal Trauma Fixation Devices Market:

Based on product, the closure device segment is expected to experience rapid growth in the market and is projected to grow at a CAGR of 6.7% from 2018 to 2025.

Based on material, the nitinol segment exhibits fastest growth and is expected to grow at a CAGR of 7.0% from 2018 to 2025.

Based on end user, the hospital & clinic segment held approximately half of the global market share in 2017 and is expected to remain dominant throughout the forecast period.

Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 7.3% during the forecast period.

Major market players

Stryker Corporation
Zimmer Holdings, Inc.
Zimmer Biomet, Inc.
Medartis
B. Braun Melsungen AG
DePuy Synthes
Smith & Nephew Plc
Wright Medical Inc.
Globus Medical Inc.
Orthopaedic Implant Company

For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/804

North America region to garner largest share through 2025

North America region held the largest share in 2017, contributing about 42% share of the total market, owing to the presence of key market players, high population base, and rise in healthcare spending. However, the Asia-Pacific region is expected to portray the fastest CAGR of 7.3% during the study period, owing to favorable reimbursement policies in the healthcare system, improved awareness about internal fixation devices among healthcare professionals, and availability of trained healthcare personnel.

Read More: https://www.alliedmarketresearch.com/internal-trauma-fixation-devices-market

Stainless steel segment to dominate the global market by 2025

In 2017, the stainless steel segment dominated the global market in terms of revenue, contributing about 43% share. This segment is anticipated to maintain this trend, as they are biocompatible, corrosion-resistant, cost-effective, and bear low risk of infection. However, the nitinol segment is estimated to register the CAGR of 7.0% during the forecast period, as they show shape memory and superelastic property. The other segments analyzed in the report include titanium, tritium, and polyether ether ketone.

Similar Reports:

Antihypertensive Drugs Market Analysis, Advancement and Outlook – 2026

Meningococcal Vaccines Market Analysis, Advancement and Outlook 2026

About Us:

Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Analytics LLP
+1 800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Multiple Sclerosis Therapies Market to Garner $28.00 billion by 2026 at 2.5% CAGR, Says AMR

Multiple Sclerosis Therapies Market

Multiple Sclerosis Therapies Market

multiple sclerosis (MS) therapies market is projected to reach $28.00 billion by 2026, registering a CAGR of 2.5% from 2019 to 2026.

PORTLAND, OREGON, UNITED STATES, October 27, 2020 /EINPresswire.com/ — Global Multiple Sclerosis Therapies Market generated $22.99 million in 2018, and is estimated to reach $28.00 million by 2026, registering a CAGR of 2.5% from 2019 to 2026.

Increase in number of pipeline drugs, surge in patient population, and rise in number of patient assistance programs (PAPs) boost the global multiple sclerosis therapies market

Download Sample Report: https://www.alliedmarketresearch.com/request-sample/1438

Covid-19 scenario:

During the coronavirus pandemic, MS therapies are getting popular among consumers as they face various health issues and intend to consolidate immunity system.

The medication centers across the globe have been closed during lockdown to avoid the spread of coronavirus.
The report offers a detailed segmentation of the global MS therapies market based on type, route of administration, and region.

Based on route of administration, the oral segment accounted for the largest share in 2018, holding nearly half of the total share, and is expected to maintain the largest share throughout the forecast period. Moreover, this segment is estimated to portray the highest CAGR of 2.8% from 2019 to 2026. The report also analyzes the Injectable, and Intravenous segment.

Based on type, the immunosuppressants segment contributed to the largest share in 2018, accounting for nearly two-thirds of the total share, and is estimated to maintain its dominant position during the forecast period. Moreover, this segment is estimated to portray the highest CAGR of 2.8% from 2019 to 2026. The report also analyzes the immunomodulators segment.

Leading market players-

Bayer AG
Biogen
Bristol-Myers Squibb Company
ABBVIE INC.
F. Hoffmann-La Roche Ltd.
Merck KGaA
Novartis AG
Pfizer Inc.
SANOFI
Teva Pharmaceutical Industries Ltd.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/1438

The oral segment to maintain its leadership position during the forecast period-

Based on route of administration, the oral segment contributed to the highest market share with more than two-fifths of the global multiple sclerosis therapies market share in 2018, and is estimated to maintain its leadership position during the forecast period. Furthermore, the segment is estimated to generate the fastest CAGR of 2.8% from 2019 to 2026. This is due to significant therapeutic advances in the new orally administered drugs approved for the MS treatment.

North America to maintain its dominant by 2026-

Based on region, North America, accounted for the highest share based on revenue, holding for nearly two-fifths of the total share of the global multiple sclerosis therapies market in 2018, owing to rise in U.S. FDA approvals for medications used in the treatment of MS and improved healthcare system in this region. However, LAMEA is estimated to portray the fastest CAGR of 3.1% from 2019 to 2026, owing to the high prevalence of MS in the Middle East countries.

Related Reports:

Osteoporosis Drugs Market – Opportunity Analysis and Industry Forecast 2026

Internal Trauma Fixation Devices Market Analysis and Industry Forecast 2025

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Analytics LLP
+1 800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Autoimmune Disease Therapeutics Market Is Expected to See Extensive Worldwide Growth

Autoimmune Disease Therapeutics Market

Autoimmune Disease Therapeutics Market

Global autoimmune disease therapeutics market is projected to reach $153,320 million by 2025, registering a CAGR of 4.2% from 2018 to 2025.

PORTLAND, OREGON, UNITED STATES, October 27, 2020 /EINPresswire.com/ — The report provides an extensive analysis of key winning strategies, changing market dynamics, market size & projections, and competitive landscape. According to the report, the global autoimmune disease therapeutics market accounted for nearly $109.83 billion in 2017, and is expected to reach $153.32 billion by 2025, growing at a CAGR of 4.2% from 2018 to 2025.

Rise in the adoption of autoimmune disease therapeutics, increase in incidence of autoimmune disease, and wide availability of advanced therapeutics are the major drivers of the global autoimmune disease therapeutics market. However, high cost associated with advanced autoimmune disease therapeutics hampers the market. On the contrary, growth opportunities in the emerging economies and strong presence of pipeline drugs are expected to create lucrative opportunities in the near future.

Request Report Sample at: https://www.alliedmarketresearch.com/request-sample/5185

Industry Key Players

Abbott Laboratories
AbbVie Inc.
Bristol-Myers Squibb Company
F. Hoffmann-La Roche AG
Novartis AG, Amgen Inc.
AstraZeneca plc.
Johnson & Johnson
Pfizer Inc.
UCB S.A.

Segmentation Analysis of the Industry

On the basis of indication, the market is bifurcated into rheumatic disease, type 1 diabetes, multiple sclerosis, inflammatory bowel disease, and others. The rheumatic disease segment held about half of the total market share in 2017 and is expected to maintain its dominance throughout the study period. Moreover, the segment is estimated to manifest the fastest CAGR of 5.2% during the study period, owing to prevalence, surge in R&D activities, and availability of advanced therapeutics.

For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/5185

Drug stores & retail pharmacies to maintain its dominant position by 2025

Drug stores & retail pharmacies accounted for nearly three-fifths of the total share in 2017 and will maintain its dominant position by 2025, owing to ease in availability offered by them and presence of large number of stores. However, online stores would grow at the fastest rate, registering a CAGR of 6.8% from 2018 to 2025, owing to rise in preference for online channels and advantages such as less expenses, enhanced convenience, and easy access to reviews of other patients.

Rheumatic disease segment to maintain its dominant share by 2025

Based on indication, rheumatic disease segment contributed nearly half of the total market share in 2017 and will maintain its dominant share by 2025. Moreover, this segment would register the highest growth rate, with a CAGR of 5.2% from 2018 to 2025. This is due to increase in prevalence, surge in R&D activities, and availability of advanced therapeutics. The report also analyzes type 1 diabetes, multiple sclerosis, inflammatory bowel disease, and others.

Similar Reports:

Intelligent Asthma Monitoring Devices Market Analysis & Forecast-2025

Body Contouring Devices Market – Opportunity Analysis & Forecast, 2018-2025

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Analytics LLP
+1 800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire